应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
NVS 诺华
交易中 11-21 13:18:06 EST
103.86
+0.77
+0.75%
最高
103.93
最低
103.03
成交量
86.87万
今开
103.16
昨收
103.09
日振幅
0.87%
总市值
2,076亿
流通市值
1,982亿
总股本
19.99亿
成交额
8,980万
换手率
0.05%
流通股本
19.08亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
医药早参丨基于癌症和炎症药物乐观前景 诺华制药上调中期销售预期
每日经济新闻 · 11-21 22:50
医药早参丨基于癌症和炎症药物乐观前景 诺华制药上调中期销售预期
基于癌症和炎症药物乐观前景,诺华上调中期销售预期
智通财经网 · 11-21 17:31
基于癌症和炎症药物乐观前景,诺华上调中期销售预期
Ratio与诺华(NVS)签订许可与合作协议
金吾财讯 · 11-18
Ratio与诺华(NVS)签订许可与合作协议
诺华(NVS.US)的镥 [177Lu] 特昔维匹肽上市申请获 CDE 受理
智通财经 · 11-13
诺华(NVS.US)的镥 [177Lu] 特昔维匹肽上市申请获 CDE 受理
金十数据整理:每日美股市场要闻速递(11月12日 周二)
美港电讯 · 11-12
金十数据整理:每日美股市场要闻速递(11月12日 周二)
BUZZ-薛定谔与诺华公司的研究合作与许可协议
Reuters · 11-12
BUZZ-薛定谔与诺华公司的研究合作与许可协议
治疗IgA肾病!诺华(NVS.US)阿曲生坦拟纳入优先审评
智通财经 · 11-12
治疗IgA肾病!诺华(NVS.US)阿曲生坦拟纳入优先审评
诺华的两步大棋
蓝鲸财经 · 11-07
诺华的两步大棋
诺华肾脏产品组合“首秀”进博会 企业表示将积极推动产品上市
证券日报 · 11-07
诺华肾脏产品组合“首秀”进博会 企业表示将积极推动产品上市
诺华与英国终止疫苗供应协议
Reuters · 11-06
诺华与英国终止疫苗供应协议
诺华制药2024财年第三财季实现净利润31.89亿美元,同比增加111.05%
市场透视 · 11-03
诺华制药2024财年第三财季实现净利润31.89亿美元,同比增加111.05%
总金额约170亿美元!辉瑞(PFE.US)、诺华(NVS.US)等最近引进了哪些在研新药?
智通财经网 · 10-30
总金额约170亿美元!辉瑞(PFE.US)、诺华(NVS.US)等最近引进了哪些在研新药?
隔夜美股全复盘(10.30)| 谷歌盘后一度涨超6%,三季度云营收超预期
格隆汇 · 10-30
隔夜美股全复盘(10.30)| 谷歌盘后一度涨超6%,三季度云营收超预期
异动解读 | 银屑病与癌症药物销售强劲 诺华制药再次上调年度利润指引
异动解读 · 10-30
异动解读 | 银屑病与癌症药物销售强劲 诺华制药再次上调年度利润指引
诺华制药盘中异动 下午盘股价大跌5.01%
市场透视 · 10-30
诺华制药盘中异动 下午盘股价大跌5.01%
金十数据整理:每日美股市场要闻速递(10月29日 周二)
美港电讯 · 10-29
金十数据整理:每日美股市场要闻速递(10月29日 周二)
银屑病与癌症药物销售强劲 诺华制药(NVS.US)再次上调年度利润指引
智通财经网 · 10-29
银屑病与癌症药物销售强劲 诺华制药(NVS.US)再次上调年度利润指引
诺华再次上调业绩指引,盈利和销售额受关键药物提振超出市场预期
环球市场播报 · 10-29
诺华再次上调业绩指引,盈利和销售额受关键药物提振超出市场预期
诺华再次上调全年业绩预期
环球市场播报 · 10-29
诺华再次上调全年业绩预期
诺华制药(NVS.N):第三季度自由现金流为60亿美元,这得益于经营活动产生的净现金流的增加。
美港电讯 · 10-29
诺华制药(NVS.N):第三季度自由现金流为60亿美元,这得益于经营活动产生的净现金流的增加。
加载更多
公司概况
公司名称:
诺华
所属市场:
NYSE
上市日期:
--
主营业务:
Novartis AG于1996年2月29日在瑞士成立。该公司提供满足全球患者和社会不断变化的需求的医疗保健解决方案。他们广泛的产品组合包括创新药物和肿瘤药物,仿制药和生物仿制药以及眼科护理设备。他们的使命是发现改善和延伸人们生活的新方法。他们的愿景是成为改变医学实践的值得信赖的领导者。他们的战略是利用科学的创新在不断增长的医疗领域提供更好的患者结果。
发行价格:
--
{"stockData":{"symbol":"NVS","market":"US","secType":"STK","nameCN":"诺华","latestPrice":103.86,"timestamp":1732213082660,"preClose":103.09,"halted":0,"volume":868670,"delay":0,"floatShares":1907865806,"shares":1999270033,"eps":8.578162,"marketStatus":"交易中","marketStatusCode":2,"change":0.77,"latestTime":"11-21 13:18:06 EST","open":103.16,"high":103.93,"low":103.03,"amount":89802731.0719,"amplitude":0.00873,"askPrice":103.86,"askSize":2,"bidPrice":103.85,"bidSize":100,"shortable":3,"etf":0,"ttmEps":8.578162,"exchange":"NYSE","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1732222800000},"adr":1,"adjPreClose":103.09,"adrRate":1,"dividendRate":0.037733,"preHourTrading":{"tag":"盘前","latestPrice":103.16,"preClose":103.09,"latestTime":"09:29 EST","volume":8107,"amount":836019.21491,"timestamp":1732199399999},"postHourTrading":{"tag":"盘后","latestPrice":103.09,"preClose":103.09,"latestTime":"19:07 EST","volume":16547,"amount":1705832.0388,"timestamp":1732147669056},"volumeRatio":1.15803,"impliedVol":0.2073,"impliedVolPercentile":0.5238},"requestUrl":"/m/hq/s/NVS","defaultTab":"news","newsList":[{"id":"2485963418","title":"医药早参丨基于癌症和炎症药物乐观前景 诺华制药上调中期销售预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2485963418","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485963418?lang=zh_cn&edition=full","pubTime":"2024-11-21 22:50","pubTimestamp":1732200618,"startTime":"0","endTime":"0","summary":"丨 2024年11月22日 星期五 丨NO.1基于癌症和炎症药物乐观前景 诺华制药上调中期销售预期11月21日,基于对新的癌症和免疫疾病药物以及神经和心血管疾病治疗药物的乐观预期,诺华制药上调了中期销售预期。公司贝伐珠单抗注射液获得国家药监局批准上市,视同通过生物类似药相似性评价。该药品获批生产和销售将对公司未来经营业绩产生积极影响。截至目前,HRS-6208胶囊相关项目累计已投入研发费用约为2378万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121225052a24b7e72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121225052a24b7e72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BJJMRZ35.SGD","BK4007","BK4532","BK4588","BK4578","IE0009355771.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","NVS","IE0002141913.USD","BK4585","IE00B4R5TH58.HKD","LU0211331839.USD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"1183551855","title":"基于癌症和炎症药物乐观前景,诺华上调中期销售预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1183551855","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183551855?lang=zh_cn&edition=full","pubTime":"2024-11-21 17:31","pubTimestamp":1732181469,"startTime":"0","endTime":"0","summary":"公司营收将以每年6%的速度增长。","market":"us","thumbnail":"https://static.tigerbbs.com/7766c80d5c26c9599970478e92d8da00","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/7766c80d5c26c9599970478e92d8da00"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1214014.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVS"],"gpt_icon":1},{"id":"2484678465","title":"Ratio与诺华(NVS)签订许可与合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2484678465","media":"金吾财讯","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484678465?lang=zh_cn&edition=full","pubTime":"2024-11-18 21:54","pubTimestamp":1731938073,"startTime":"0","endTime":"0","summary":"金吾财讯 | 药物研发和制造公司Ratio Therapeutics于11月18日宣布,与诺华制药(NVS)的子公司Novartis Pharma签署了一项全球独家许可与合作协议,该合作利用Ratio的放射性配体疗法发现和开发专长及其技术平台,开发治疗癌症的生长抑素受体2(SSTR2)放射性治疗候选药物。根据协议条款,Ratio将获得高达7.45亿美元的预付款和潜在的里程碑付款,并有资格获得分级特许权使用费。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"282120","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","IE0002141913.USD","BK4585","IE00BJT1NW94.SGD","IE0009355771.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","BK4532","LU0211331839.USD","BK4578","NVS"],"gpt_icon":0},{"id":"2483151011","title":"诺华(NVS.US)的镥 [177Lu] 特昔维匹肽上市申请获 CDE 受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2483151011","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483151011?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:54","pubTimestamp":1731466452,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,11 月 13 日,诺华的镥 [177Lu] 特昔维匹肽上市申请获 CDE 受理。该药是 FDA 批准的首个针对去势抵抗性前列腺癌患者的靶向放射性配体疗法,本次是在国内首次报上市。以放射配体疗法为代表的核药是诺华重金布局的领域。除了 Pluvicto,诺华还有一款核药 Lutathera 也已获批上市,用于生长抑素受体阳性胃肠胰神经内分泌肿瘤成人患者, 后又获批用于12 岁及以上儿童患者。Lutathera 2023 年销售额达 6.05 亿美元,2024 前三个季度销售额为 5.34 亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210232.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0002141913.USD","BK4017","BK4578","NVS","IE0009355771.USD","LU0211331839.USD","BK4588","BK4585","BK4532","BK4007","IE00B2B36J28.USD","IE00B4R5TH58.HKD","CDE","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2482704449","title":"金十数据整理:每日美股市场要闻速递(11月12日 周二)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482704449","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482704449?lang=zh_cn&edition=full","pubTime":"2024-11-12 21:31","pubTimestamp":1731418319,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4532","BK4513","BK4515","IE00BVYPNW00.USD","NQGM","161631","RDSA.UK","IE0009355771.USD","BK4526","LU0792757196.USD","LU0320765992.SGD","RDS.A","BK4563","SHEL","LU1162221912.USD","BK4533","IE00BGHQF631.EUR","IE00B19Z3B42.SGD","CDE","LU0889566641.SGD","LU2462157665.USD","BK4078","AZN","BK4017","LU0109394709.USD","01477","GPRO","JNJ","DELL","LU1066053197.SGD","LU0345769128.USD","BK4592","LU0345769631.USD","AVNW","BK4127","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","BA","TIGR","IE00BJT1NW94.SGD","HUYA","LU0640476718.USD","BK4578","NVS","RDS.B","IE00B3PB1722.GBP","BK4007","BK4588","IE0002141913.USD"],"gpt_icon":0},{"id":"2482703103","title":"BUZZ-薛定谔与诺华公司的研究合作与许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2482703103","media":"Reuters","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482703103?lang=zh_cn&edition=full","pubTime":"2024-11-12 20:17","pubTimestamp":1731413820,"startTime":"0","endTime":"0","summary":" 11月12日 - ** 制药软件公司Schrodinger 股价盘前上涨6.5%至20.81美元** 该公司宣布与诺华 达成研究合作与许可协议,\"将多个候选开发项目纳入诺华的产品组合,以便进一步开发\"。** 还宣布扩大与诺华公司为期三年的软件协议** 根据协议条款,co 将获得 1.5 亿美元的预付款,并有资格获得高达 8.92 亿美元的里程碑付款。** 此外,Co 还有资格获得高达 13.8 亿美元的商业里程碑款项,以及诺华公司商业化的每种产品净销售额的中个位数至低两位数的分级特许权使用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4167","SDGR","IE0009355771.USD","BK4585","BK4588","IE0002141913.USD","LU0211331839.USD","BK4007","BK4532","BK4578"],"gpt_icon":0},{"id":"2482974614","title":"治疗IgA肾病!诺华(NVS.US)阿曲生坦拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2482974614","media":"智通财经","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482974614?lang=zh_cn&edition=full","pubTime":"2024-11-12 13:45","pubTimestamp":1731390335,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,11 月 12 日,CDE官网显示,诺华的盐酸阿曲生坦片拟纳入优先审评,适应症为用于降低有疾病进展风险的原发性免疫球蛋白A肾病成人患者的蛋白尿。阿曲生坦有可能添加到目前的支持疗法中,以减少持续性蛋白尿并保护广大患者群体的肾功能。临床前模型也表明阿曲生坦可以减少IgAN中的炎症和纤维化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4007","BK4585","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0211331839.USD","NVS","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4532","BK4578","IE0002141913.USD"],"gpt_icon":0},{"id":"2481905593","title":"诺华的两步大棋","url":"https://stock-news.laohu8.com/highlight/detail?id=2481905593","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481905593?lang=zh_cn&edition=full","pubTime":"2024-11-07 19:47","pubTimestamp":1730980071,"startTime":"0","endTime":"0","summary":"诺华,在一众大药企中算得上是一个独特的存在。诺华却不“跟风”,而是加速瘦身,从不具优势的领域撤退,进一步加大新兴技术平台布局,包括靶向蛋白质降解技术、细胞疗法、基因疗法、放射性配体疗法以及RNA疗法。在今年的进博会上,诺华重点展示了放射配体疗法、长效降脂药以及肾病管线组合,并设立专区,展示其深耕国内县域市场的决心。本届进博会上,诺华的放射配体疗法是“展品推动重大投资及落地”的典型例子。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/244059","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IE00BJT1NW94.SGD","BK4532","BK4007","NVS","LU0211331839.USD","IE0002141913.USD","BK4588","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4578","BK4585","IE0009355771.USD"],"gpt_icon":0},{"id":"2481921375","title":"诺华肾脏产品组合“首秀”进博会 企业表示将积极推动产品上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2481921375","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481921375?lang=zh_cn&edition=full","pubTime":"2024-11-07 16:10","pubTimestamp":1730967054,"startTime":"0","endTime":"0","summary":"本报讯(记者张文湘见习记者金婉霞)第七届中国国际进口博览会(简称:进博会)正在举行。记者在现场看到,诺华旗下用于IgA肾病(IgAN)治疗的创新药物组合阿曲生坦及飞赫达(盐酸伊普可泮胶囊)首度联合亮相。记者从诺华方面进一步获悉,诺华拟在肾病领域打出“组合拳”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411073232688882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK4007","IE0002141913.USD","BK4585","IE00BJT1NW94.SGD","IE0009355771.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","BK4532","LU0211331839.USD","BK4578","NVS"],"gpt_icon":0},{"id":"2481657166","title":"诺华与英国终止疫苗供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2481657166","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481657166?lang=zh_cn&edition=full","pubTime":"2024-11-06 06:07","pubTimestamp":1730844430,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透11月5日 - Novavax 周二表示,该公司已与英国卫生安全局就COVID-19疫苗供应协议达成了终止和和解协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4568","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0211331839.USD","BK4578","BK4585","IE00B2B36J28.USD","BK4547","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","BK4139","NVAX","IE0002141913.USD","IE00BFTCPJ56.SGD","NVS","BK4007","BK4532"],"gpt_icon":0},{"id":"2480808875","title":"诺华制药2024财年第三财季实现净利润31.89亿美元,同比增加111.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480808875","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480808875?lang=zh_cn&edition=full","pubTime":"2024-11-03 00:00","pubTimestamp":1730563226,"startTime":"0","endTime":"0","summary":"11月3日,诺华制药公布财报,公告显示公司2024财年第三财季净利润为31.89亿美元,同比增加111.05%;其中营业收入为128.23亿美元,同比增加8.84%,每股基本收益为1.59美元。从资产负债表来看,诺华制药总负债600.83亿美元,其中短期债务68.13亿美元,资产负债比为0.01,流动比率为1.12。机构评级:截至2024年11月3日,当前有18家机构对诺华制药目标价做出预测,其中目标均价为119.67美元,其中最低目标价为97.88美元,最高目标价为143.93美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000032a20f7a92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000032a20f7a92&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVS"],"gpt_icon":0},{"id":"2479301225","title":"总金额约170亿美元!辉瑞(PFE.US)、诺华(NVS.US)等最近引进了哪些在研新药?","url":"https://stock-news.laohu8.com/highlight/detail?id=2479301225","media":"智通财经网","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479301225?lang=zh_cn&edition=full","pubTime":"2024-10-30 15:27","pubTimestamp":1730273237,"startTime":"0","endTime":"0","summary":"近几年来,新药授权合作已成为行业重要趋势之一。公开资料显示,仅今年10月以来,全球范围内发生的授权合作事件有近30起,包括多家国际药企均有动作。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20241030/20241030153231_20918.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20241030/20241030153231_20918.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1203468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4533","IE00B19Z3581.USD","IE00BJT1NW94.SGD","LU0868494617.USD","LU0306807586.USD","NVS","SG9999002224.SGD","LU1894683264.USD","SG9999003800.SGD","LU0985481810.HKD","LU0321505439.SGD","LU0321505868.SGD","IE00BJJMRZ35.SGD","IE0009355771.USD","BK4592","BK4534","LU0211331839.USD","LU0456855351.SGD","LU1057294990.SGD","PFE","BK4585","IE0002270589.USD","LU0058720904.USD","IE00B4R5TH58.HKD","SG9999001176.USD","IE00B19Z3B42.SGD","IE0002141913.USD","BK4578","BK4532","IE000M9KFDE8.USD","LU1894683348.USD","BK4588","LU0225284248.USD","BK4007","IE00BBT3K403.USD","LU0122379950.USD","SGXZ57979304.SGD","LU1066053197.SGD","LU0170899867.USD","BK4568","LU0225771236.USD","LU1883839398.USD","LU0306806265.USD","IE00BFTCPJ56.SGD","IE00BLSP4239.USD","SG9999013999.USD","LU0289739699.SGD","IE00BLSP4452.SGD","IE00B2B36J28.USD","BK4581"],"gpt_icon":1},{"id":"2479497260","title":"隔夜美股全复盘(10.30)| 谷歌盘后一度涨超6%,三季度云营收超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2479497260","media":"格隆汇","labels":["viewpoints"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479497260?lang=zh_cn&edition=full","pubTime":"2024-10-30 07:57","pubTimestamp":1730246237,"startTime":"0","endTime":"0","summary":"谷歌盘后一度涨超6%,三季度云营收超预期","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"e0135d03713d4d75e822fef035a4eb15","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1236616","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"viewpoints","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["PYPL","GOOGL","GOOG","NVS","AMD","AZN","AAPL","RDDT","DJT","BA"],"gpt_icon":1},{"id":"1162801824","title":"异动解读 | 银屑病与癌症药物销售强劲 诺华制药再次上调年度利润指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1162801824","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162801824?lang=zh_cn&edition=full","pubTime":"2024-10-30 02:08","pubTimestamp":1730225318,"startTime":"0","endTime":"0","summary":"瑞士制药巨头诺华制药(NVS.US)连续第三个季度上调了年度利润指引,这得益于其治疗牛皮癣和癌症的重磅药物销量的增长。\n\n诺华制药Q3营收同比增长10%,高于预期的7%增幅。核心每股收益增长20%,高于预期的12%增幅。该公司银屑病药物Cosentyx的销售额上升至16.9亿美元,高于分析师预计的15.6亿美元。癌症药物Kisqali和备受关注的前列腺癌药物Pluvicto的收入也略高于预期。\n\n得益于上述核心产品的增长,诺华制药最新预计2024年核心营业利润增幅将在17%-19%区间,而销售额将低两位数增长,这两个目标都处于其早期指引范围的顶端。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVS"],"gpt_icon":0},{"id":"2479237023","title":"诺华制药盘中异动 下午盘股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479237023","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479237023?lang=zh_cn&edition=full","pubTime":"2024-10-30 01:53","pubTimestamp":1730224384,"startTime":"0","endTime":"0","summary":"北京时间2024年10月30日01时53分,诺华制药股票出现异动,股价快速跳水5.01%。诺华制药股票所在的制药行业中,整体涨幅为0.15%。消息层面,截至01时53分,《银屑病与癌症药物销售强劲 诺华制药再次上调年度利润指引》资讯为影响诺华制药的重要信息。诺华制药Q3营收同比增长10%,高于预期的7%增幅。诺华制药股价今年上涨了18%,超过了彭博追踪欧洲制药公司的指数13%的涨幅。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030015305971a2fd6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241030015305971a2fd6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LU0211331839.USD","BK4588","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE0002141913.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","NVS","IE00BJT1NW94.SGD","BK4532","BK4578","BK4007"],"gpt_icon":0},{"id":"2479401213","title":"金十数据整理:每日美股市场要闻速递(10月29日 周二)","url":"https://stock-news.laohu8.com/highlight/detail?id=2479401213","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479401213?lang=zh_cn&edition=full","pubTime":"2024-10-29 20:35","pubTimestamp":1730205329,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0187121727.USD","BK4587","DJT","BA","BK4568","LU1861220207.SGD","LU0724617625.USD","LU0433182093.SGD","LU1244550577.SGD","MCD","IE00BDCRKT87.USD","IE00BMPRXN33.USD","LU0106261372.USD","PYPL","BK6088","IE000ITXATA3.USD","BK4551","LU0786609619.USD","LU2360107671.USD","IE00BMPRXQ63.HKD","LU0289960550.SGD","IE00B4YYXB79.USD","IE00BBT3K403.USD","AZN","IE00BQXX3F31.USD","BK4564","01477","IE00B5949003.HKD","IE00BHPRN162.USD","159813","BK4528","BK4574","LU0225283273.USD","BK4573","LU0053666078.USD","LU0109391861.USD","IE00B1BXHZ80.USD","NVS","IE00BN8TJ469.HKD","BLZ.SI","IE0005OL40V9.USD","HK0000320264.USD","LU0080751232.USD","HK0000306685.HKD","LU1718418525.SGD"],"gpt_icon":0},{"id":"2479447402","title":"银屑病与癌症药物销售强劲 诺华制药(NVS.US)再次上调年度利润指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2479447402","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479447402?lang=zh_cn&edition=full","pubTime":"2024-10-29 15:05","pubTimestamp":1730185500,"startTime":"0","endTime":"0","summary":"智通财经获悉,诺华制药连续第三个季度上调了年度利润指引,这得益于其治疗牛皮癣和癌症的重磅药物销量的增长。该公司银屑病药物Cosentyx的销售额上升至16.9亿美元,高于分析师预计的15.6亿美元。诺华制药在经历了多年的不断变化后,专注于增长。根据协议,诺华制药将以1.5亿美元的预付款获得MRT-6160和其他VAV1分子胶降解剂的全球独家开发、生产和商业化权利。诺华制药股价今年上涨了18%,超过了彭博追踪欧洲制药公司的指数13%的涨幅。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/hkstocknews/2024-10-29/doc-incufcxx8704242.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkstocknews/2024-10-29/doc-incufcxx8704242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","IE00BJJMRZ35.SGD","BK4588","BK1574","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0211331839.USD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4578","IE00B4R5TH58.HKD","BK4007","IE00B2B36J28.USD","BK1191","BK4532","BK4585","NVS"],"gpt_icon":0},{"id":"2479442911","title":"诺华再次上调业绩指引,盈利和销售额受关键药物提振超出市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2479442911","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479442911?lang=zh_cn&edition=full","pubTime":"2024-10-29 14:57","pubTimestamp":1730185020,"startTime":"0","endTime":"0","summary":"诺华(Novartis)今年第三次上调了全年业绩指引,此前得益于其关键药物收入的提振,该公司第三季度利润和销售额实现增长并超过分析师预期。\n 这家瑞士制药巨头周二表示,目前预计2024年核心营业利润增幅将在10-20%区间的高段,此前该公司预期增幅在此区间的中、高段。\n 诺华目前预计全年销售额将实现低两位数增幅,此前该公司的预期为高个位数至低两位数增幅。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:陈钰嘉","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/usstock/c/2024-10-29/doc-incufcxz7777041.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-10-29/doc-incufcxz7777041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE0002141913.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4532","IE0009355771.USD","BK4588","BK4007","NVS","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU0211331839.USD","BK4585","BK4578"],"gpt_icon":0},{"id":"2479844474","title":"诺华再次上调全年业绩预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2479844474","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479844474?lang=zh_cn&edition=full","pubTime":"2024-10-29 14:50","pubTimestamp":1730184600,"startTime":"0","endTime":"0","summary":"瑞士制药巨头诺华集团周二连续第三个季度上调了年度利润预期,得益于其治疗牛皮癣和癌症的重磅药物销量的增长。\n 该公司表示,目前预计今年的核心营业利润将实现高两位数的增长,而销售额将实现低两位数的增长。\n 诺华此前曾预测,今年核心营业利润将增长将呈中到高两位数增长,而销售额将以高个位数到低两位数的比例增长。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:于健 SF069","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/usstock/c/2024-10-29/doc-incufcyc4551969.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-10-29/doc-incufcyc4551969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE0009355771.USD","BK4532","BK4588","IE00BFTCPJ56.SGD","LU0211331839.USD","BK4007","IE00BJJMRZ35.SGD","BK4585","NVS","IE0002141913.USD","BK4578","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2479449535","title":"诺华制药(NVS.N):第三季度自由现金流为60亿美元,这得益于经营活动产生的净现金流的增加。","url":"https://stock-news.laohu8.com/highlight/detail?id=2479449535","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479449535?lang=zh_cn&edition=full","pubTime":"2024-10-29 14:11","pubTimestamp":1730182292,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["NVS","IE0002141913.USD","LU0211331839.USD","BK1191","BK4588","IE00BJT1NW94.SGD","01477","BK4578","IE00BJJMRZ35.SGD","BK4585","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4532","BK1574","BK4007","IE00BFTCPJ56.SGD","IE0009355771.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novartis.com","stockEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":-0.1092},{"period":"3month","weight":-0.1246},{"period":"6month","weight":0.0255},{"period":"1year","weight":0.0696},{"period":"ytd","weight":0.021}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":0.0118},{"period":"3month","weight":0.0616},{"period":"6month","weight":0.1153},{"period":"1year","weight":0.3028},{"period":"ytd","weight":0.2423}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novartis AG于1996年2月29日在瑞士成立。该公司提供满足全球患者和社会不断变化的需求的医疗保健解决方案。他们广泛的产品组合包括创新药物和肿瘤药物,仿制药和生物仿制药以及眼科护理设备。他们的使命是发现改善和延伸人们生活的新方法。他们的愿景是成为改变医学实践的值得信赖的领导者。他们的战略是利用科学的创新在不断增长的医疗领域提供更好的患者结果。","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.014981},{"month":2,"riseRate":0.416667,"avgChangeRate":-0.012188},{"month":3,"riseRate":0.5,"avgChangeRate":0.000575},{"month":4,"riseRate":0.708333,"avgChangeRate":0.018746},{"month":5,"riseRate":0.666667,"avgChangeRate":0.008804},{"month":6,"riseRate":0.56,"avgChangeRate":0.010664},{"month":7,"riseRate":0.72,"avgChangeRate":0.014267},{"month":8,"riseRate":0.4,"avgChangeRate":-0.003307},{"month":9,"riseRate":0.68,"avgChangeRate":0.009526},{"month":10,"riseRate":0.44,"avgChangeRate":-0.01226},{"month":11,"riseRate":0.6,"avgChangeRate":0.013942},{"month":12,"riseRate":0.708333,"avgChangeRate":0.0233}],"exchange":"NYSE","name":"诺华","nameEN":"Novartis AG"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺华,NVS,诺华股票,诺华股票老虎,诺华股票老虎国际,诺华行情,诺华股票行情,诺华股价,诺华股市,诺华股票价格,诺华股票交易,诺华股票购买,诺华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}